159 related articles for article (PubMed ID: 38642245)
1. Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Yoshinami T; Nagai SE; Hattori M; Okamura T; Watanabe K; Nakayama T; Masuda H; Tsuneizumi M; Takabatake D; Harao M; Yoshino H; Mori N; Yasojima H; Oshiro C; Iwase M; Yamaguchi M; Sangai T; Kosaka N; Tajima K; Masuda N
Breast Cancer; 2024 Apr; ():. PubMed ID: 38642245
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of palbociclib plus endocrine therapy for patients with HR
Zhong B; Zhang J; Wu J; Sun L; Li S; Zeng X; Gan L
Ann Transl Med; 2022 Mar; 10(6):362. PubMed ID: 35434007
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis.
Brufsky A; Liu X; Li B; McRoy L; Layman RM
Front Oncol; 2022; 12():865292. PubMed ID: 35860587
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older.
Brufsky A; Liu X; Li B; McRoy L; Chen C; Layman RM; Rugo HS
Front Oncol; 2023; 13():1237751. PubMed ID: 37841423
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
DeMichele A; Cristofanilli M; Brufsky A; Liu X; Mardekian J; McRoy L; Layman RM; Emir B; Torres MA; Rugo HS; Finn RS
Breast Cancer Res; 2021 Mar; 23(1):37. PubMed ID: 33761995
[TBL] [Abstract][Full Text] [Related]
6. RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world use.
Petracci F; Abuin GG; Pini A; Chacón M
Ecancermedicalscience; 2020; 14():1058. PubMed ID: 32582373
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of male patients with HR+/HER2- advanced breast cancer receiving palbociclib in the real-world POLARIS study.
Blum JL; DiCristo C; Gordon D; Karuturi MS; Oubre D; Jepsen E; Cuevas J; Lakhanpal S; Montelongo MZ; Zhang Z; Cappelleri JC; Wang Y; Tripathy D
Breast Cancer Res Treat; 2024 Feb; 203(3):463-475. PubMed ID: 37903899
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database.
Rugo HS; Liu X; Li B; McRoy L; Chen C; Layman RM; Brufsky A
Int J Cancer; 2024 Feb; 154(4):701-711. PubMed ID: 37831416
[TBL] [Abstract][Full Text] [Related]
9. Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.
DeMichele A; Robert N; Chen C; Kim S; Zhang Z; Lu DR; Aguilar KM; Wang Y; Li B; Schneeweiss S; Rassen JA; Gaffney M; McRoy L
Target Oncol; 2023 Jul; 18(4):543-558. PubMed ID: 37428347
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.
Ha MJ; Singareeka Raghavendra A; Kettner NM; Qiao W; Damodaran S; Layman RM; Hunt KK; Shen Y; Tripathy D; Keyomarsi K
Int J Cancer; 2022 Jun; 150(12):2025-2037. PubMed ID: 35133007
[TBL] [Abstract][Full Text] [Related]
11. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib in advanced stage hormone receptor-positive breast cancer: real-world data from a Chilean multicentre registry.
Walbaum B; Reyes JM; Rodriguez P; Muñiz S; Medina L; Ibañez C; Merino T; Pinto MP; Bravo ML; Acevedo F; Bennett J; Sanchez C
Ecancermedicalscience; 2023; 17():1636. PubMed ID: 38414945
[TBL] [Abstract][Full Text] [Related]
13. Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2- advanced/metastatic breast cancer in Japan: Results from the IRIS study.
Mycock K; Zhan L; Hart K; Taylor-Stokes G; Milligan G; Atkinson C; Mitra D
Cancer Treat Res Commun; 2022; 32():100573. PubMed ID: 35567914
[TBL] [Abstract][Full Text] [Related]
14. Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer.
Rugo HS; Liu X; Li B; McRoy L; Layman RM; Brufsky A
Breast; 2023 Jun; 69():375-381. PubMed ID: 37080011
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
16. Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis.
Patt D; Liu X; Li B; McRoy L; Layman RM; Brufsky A
Clin Breast Cancer; 2022 Aug; 22(6):601-610. PubMed ID: 35643624
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract][Full Text] [Related]
18. Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.
Robert N; Chen C; Kim S; Zhang Z; Aguilar KM; Wang Y; Li B; Gaffney M; Huang X; McRoy L
Future Oncol; 2024 Apr; 20(12):761-780. PubMed ID: 38231045
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China.
Yang J; Zhao B; Ling X; Li D; Zhao J; Lv Y; Wang G; Liu X; Li N; Yang J
BMC Cancer; 2023 Jan; 23(1):103. PubMed ID: 36717797
[TBL] [Abstract][Full Text] [Related]
20. Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer.
Rugo HS; Liu X; Li B; McRoy L; Chen C; Layman RM; Brufsky A
Oncologist; 2023 Oct; 28(10):866-874. PubMed ID: 37487056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
